Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. · 2020
Read Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. by Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7426442.txt.
Introduction
Shah and co-authors review the immune response to SARS-CoV-2, the virus that causes COVID-19. They draw lessons from past coronaviruses such as SARS-CoV and MERS-CoV. The virus attacks the airways and can cause pneumonia and low lymphocyte counts.
The review traces how B cells and T cells react to spike and nucleocapsid proteins. It covers antibody output, cytokine release, and cell killing in the acute phase. Gene variants in the MHC system shape how well viral pieces are shown to T cells. Memory T cells from past infections may protect, yet cross-reaction can also harm tissue. The authors survey drug trials and convalescent plasma use. Work on neutralizing antibodies and cytokine control closes the review.
Catalog record
| CREATOR | Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 94 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past By Vibhuti Kumar Shah, Priyanka Firmal, Aftab Alam, Dipyaman Ganguly, Samit Chattopadhyay Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2020.01949 ABSTRACT After the 1918 flu pandemic, the world is again facing a similar situation. However, the advancement in medical science has made it possible to identify that the novel infectious agent is from the coronavirus family. Rapid genome sequencing by various groups helped in identifying the structure and function of the virus, its immunogenicity in diverse populations, and potential preventive measures. Coronavirus attacks the respiratory system, causing pneumonia and lymphopenia in infected individuals. Viral components like spike and nucleocapsid proteins trigger an immune response in the host to eliminate the virus. These viral antigens can be either recognized by the B cells or presented by MHC complexes to the T cells, resulting in antibody production, increased cytokine secretion, and cytolytic activity in the acute phase of infection. Genetic polymorphism in MHC enables it to present some of the T cell epitopes very well over the other MHC alleles. The association of MHC alleles and its downregulated expression has been correlated with disease severity against influenza and coronaviruses. Studies have reported that infected individuals can, after recovery, induce strong protective responses by generating a memory T-cell pool against SARS-CoV and MERS-CoV. These memory T cells were not persistent in the long term and, upon reactivation, caused local damage due to cross-reactivity. So far, the reports suggest that SARS-CoV-2, which is highly contagious, shows related symptoms in three different stages and develops an exhaustive T-cell pool at higher loads of viral infection. As there are no specific treatments available for this novel coronavirus, numerous small molecular drugs that are being used for the treatment of diseases like SARS, MERS, HIV, ebola, malaria, and tuberculosis are being given to COVID-19 patients, and clinical trials for many such drugs have already begun. A classical immunotherapy of convalescent plasma transfusion from recovered patients has also been initiated for the neutralization of viremia in terminally ill COVID-19 patients. Due to the limitations of plasma transfusion, researchers are now focusing on developing neutralizing antibodies against virus particles along with immuno-modulation of cytokines like IL-6, Type I interferons (IFNs), and TNF-α that could help in combating the infection. This review highlights the similarities of the coronaviruses that caused SARS and MERS to the novel SARS-CoV-2 in relation to their pathogenicity and immunogenicity and also focuses on various treatment strategies that could be employed for curing COVID-19. INTRODUCTION The whole world is currently confronting a crisis situation that first appeared in late December 2019 as merely a few cases of pneumonia in Wuhan, China. The patients were exhibiting common symptoms like fever, dry cough, sore throat, breathlessness, and fatigue. Sample swabs from the oral cavity and anal region were collected along with the blood and Bronchoalveolar Lavage Fluid (BALF) from all seven of the patients, irrespective of their age and gender, which were then sent to the Wuhan Institute of Virology for further examination. As the outbreak initiated at the seafood market with the onset of winter, similar to that of the previous Severe Acute Respiratory Syndrome (SARS) infection, the scientists first screened the samples using pan-CoV qPCR primers. Surprisingly, five samples were reported positive for coronavirus. Thorough investigation employing next-generation sequencing and phylogenetic analysis led to the identification of the causative agent of this respiratory disease, a novel coronavirus (2019-nCoV) (1). As more cases started to appear around the world, on February 11, 2020, the World Health Organization assigned a name, COrona VIrus Disease 2019 or COVID-19, to the disease and declared it a pandemic on March 11, 2020. The virus was renamed from 2019-nCoV to SARS-CoV-2 by the International Committee on Taxonomy of Viruses on the basis of its genetic similarity to a previously known coronavirus, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) (2). Transmission of SARS-CoV-2 occurs when a healthy individual inhales or comes into contact with respiratory droplets from an infected person. The average incubation period before patients exhibit disease symptoms ranges from 2 to 14 days (3). Before the spread of COVID-19, SARS emerged as an epidemic in 2003, followed by Middle East respiratory syndrome (MERS) in 2012, both caused by a novel coronavirus of zoonotic origin and assigned to the genus Betacoronavirus (4). The worldwide outbreak of SARS-CoV-2 has put life on hold, having a major impact on the world's economy, and has claimed ~436,167 lives globally as of June 15, 2020 (5, 6). Unlike previous episodes of coronavirus spread, where it took months to identify the cause of infection and perform genome sequencing (7), advancement in science and technology made it possible to identify the causative organism swiftly. Within a few weeks of the outbreak, different laboratories across the world had sequenced the whole viral genome and had also provided structural and functional insights into the essential proteins required by the virus for its survival. These immediate scientific inputs helped with developing diagnostic kits and defining treatment strategies for effective prognosis and prevention (8–10). In this review, we are emphasizing the immunological aspect of SARS-CoV-2 pathogenesis by taking into consideration the previous experimental and clinical knowledge obtained from the coronaviruses that were responsible for causing SARS and MERS. This approach will assist in utilizing immunotherapies, repurposing the previously approved antiviral drugs, and developing therapeutic vaccines specific to novel coronavirus more effectively. CLASSIFICATION AND COMPARISON OF SARS-COV-2 Initial genome sequencing and phylogenetic analysis of novel coronavirus SARS-CoV-2 has shown that it is genetically similar to previously known coronavirus SARS-CoV and hence is placed under the family Coronaviridae. Coronavirus contains positive-sense single-stranded RNA (+ve ssRNA) as its genetic material, which can be about 30 kb in length and is mostly protected by an outer fatty layer of an envelope that also helps the virus to evade host immune response and assists its entry inside the host cell (11, 12). The subfamily Coronavirinae is further subdivided into four genera, namely alpha-, beta-, gamma-, and delta- coronavirus (α-CoV, β-CoV, γ-CoV, and δ-CoV). Viruses having the potential to infect humans are placed under the genus α-CoV and β-CoV (SARS-CoV & MERS-CoV), whereas viruses of γ-CoV and δ-CoV genera are mostly known to infect avians and pigs (13). The novel coronavirus, SARS-CoV-2 falls under the genus β-CoV, as it shares 88% sequence identity with SARS-CoV-like coronaviruses (derived from bat) but is only 79% identical to SARS-CoV and 50% identical to MERS-CoV (3). Thus, it can be deduced by its genome identity that the immediate host of this virus could be a bat, which then transmitted it to some unknown intermediate host that acted as a source for the transmission of the virus to humans. Like those of SARS-CoV and MERS-CoV, the SARS-CoV-2 genome comprises of 12 open reading frames (ORFs) in number. At the 5′ end of the viral genome, overlapping ORFs 1a and 1b are present that encode the RNA polymerase and other non-structural proteins of the virus and occupy approximately two-thirds of the genome. Genes encoding structural proteins such as spike (S), membrane (M), envelope (E), and nucleocapsid (N), are present in the remaining one-third of its genome spanning from the 5′ to the 3′ terminal, along